Susan Iannaccone, MD
I have been involved in designing and directing clinical trials in pediatric neuromuscular disease for 30
years. I am currently Co-Director of the MDA Pediatric Care Center at Childrens Health (CH). Since 2015,
I have been Associate Director of the UTSW Wellstone Muscular Dystrophy Center funded by NIH, led by
Dr. Eric Olson. I am co-Chair of the Administrative Core for the Wellstone Center. I was PI and leader for
an NIH sponsored clinical trials group, AmSMART from 2000 through 2008, NIH funded, which established
for the first time reliability and validity for outcome measures in a young spinal muscular atrophy (SMA)
population. I was a member of the Outcomes Committee for the International Coordinating Committee for
SMA and Co-chair of the panel to develop Common Data Elements for Pediatric Neuromuscular Disease,
a project of the NINDS. I was a member of the panels that developed CDEs for congenital muscular
dystrophy and for SMA. I was an invited member of a Steering Committee to govern the project for
conducting IND enabling toxicology studies for scAAV9-SMN gene therapy. I have worked closely over
many years with several patient advocacy/volunteer groups including the Muscular Dystrophy Association,
Parent Project for DMD and Cure SMA. Furthermore, I served on the International Standard of Care
Committees for Congenital Muscular Dystrophies, SMA and the DMD Study Group. I serve on research
grant review committees as well as several planning committees and panels for patient groups and the
NIH. I am CoInvestigator for the UT Southwestern NeuroNEXT grant from NINDS which has been renewed
by NIH for the next 5 years (2018-2023). I have trained/mentored >20 pediatric neuromuscular fellows and
medical students, many of whom are currently in academic pediatric neurology positions. I hold 2-3
pediatric neuromuscular clinics per week, all of which are official MDA sponsored clinics. A large majority
of children diagnosed with DMD/SMA in north Texas are referred to my team either by their PCP, another
child neurologist or by parents who read about our program on the internet.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BiogenDate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AvexisDate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:SareptaDate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PTC TherapeuticsDate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:RegeneronDate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Scholar RockDate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NIHDate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:MDADate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Cure SMADate added:Date updated:08/20/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Parent Project for Muscular DystrophyDate added:Date updated:08/20/2024
Pages
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.